Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases

Non-small cell lung cancer (NSCLC) continues to be one of the major causes of cancer-related deaths worldwide, and brain metastases are the major cause of death in NSCLC patients. With recent advances in understanding the underlying molecular mechanism of NSCLC development and progression, mutations...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ling-Ling Kong, Lin-Lin Wang, Li-Gang Xing, Jin-Ming Yu
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2017
Materias:	Non-small cell lung cancer Brain metastases Epidermal growth factor receptor mutation Tyrosine kinase inhibitors Therapeutic outcomes Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/aaca3257021e4c7abcefa74029c838db
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aaca3257021e4c7abcefa74029c838db
record_format	dspace
spelling	oai:doaj.org-article:aaca3257021e4c7abcefa74029c838db2021-12-02T12:54:49ZCurrent progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases2095-882X10.1016/j.cdtm.2017.11.001https://doaj.org/article/aaca3257021e4c7abcefa74029c838db2017-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X17300762https://doaj.org/toc/2095-882XNon-small cell lung cancer (NSCLC) continues to be one of the major causes of cancer-related deaths worldwide, and brain metastases are the major cause of death in NSCLC patients. With recent advances in understanding the underlying molecular mechanism of NSCLC development and progression, mutations in epidermal growth factor receptor (EGFR) have been recognized as a key predictor of therapeutic sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Using EGFR-TKI alone or in combination with standard treatments such as whole-brain radiotherapy and surgery has been an effective strategy for the management of brain metastasis. Particularly, a newer generation of EGFR-TKIs, including osimertinib and AZD3759, has been developed. These new EGFR-TKIs can cross the blood–brain barrier and potentially treat EGFR-TKI resistance and improve prognosis. In this article, current progress and outcomes of clinical trials on the use of EGFR-TKIs for treating NSCLC patients with brain metastasis will be reviewed.Ling-Ling KongLin-Lin WangLi-Gang XingJin-Ming YuKeAi Communications Co., Ltd.articleNon-small cell lung cancerBrain metastasesEpidermal growth factor receptor mutationTyrosine kinase inhibitorsTherapeutic outcomesMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 3, Iss 4, Pp 221-229 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Non-small cell lung cancer Brain metastases Epidermal growth factor receptor mutation Tyrosine kinase inhibitors Therapeutic outcomes Medicine (General) R5-920
spellingShingle	Non-small cell lung cancer Brain metastases Epidermal growth factor receptor mutation Tyrosine kinase inhibitors Therapeutic outcomes Medicine (General) R5-920 Ling-Ling Kong Lin-Lin Wang Li-Gang Xing Jin-Ming Yu Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
description	Non-small cell lung cancer (NSCLC) continues to be one of the major causes of cancer-related deaths worldwide, and brain metastases are the major cause of death in NSCLC patients. With recent advances in understanding the underlying molecular mechanism of NSCLC development and progression, mutations in epidermal growth factor receptor (EGFR) have been recognized as a key predictor of therapeutic sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Using EGFR-TKI alone or in combination with standard treatments such as whole-brain radiotherapy and surgery has been an effective strategy for the management of brain metastasis. Particularly, a newer generation of EGFR-TKIs, including osimertinib and AZD3759, has been developed. These new EGFR-TKIs can cross the blood–brain barrier and potentially treat EGFR-TKI resistance and improve prognosis. In this article, current progress and outcomes of clinical trials on the use of EGFR-TKIs for treating NSCLC patients with brain metastasis will be reviewed.
format	article
author	Ling-Ling Kong Lin-Lin Wang Li-Gang Xing Jin-Ming Yu
author_facet	Ling-Ling Kong Lin-Lin Wang Li-Gang Xing Jin-Ming Yu
author_sort	Ling-Ling Kong
title	Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
title_short	Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
title_full	Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
title_fullStr	Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
title_full_unstemmed	Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
title_sort	current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
publisher	KeAi Communications Co., Ltd.
publishDate	2017
url	https://doaj.org/article/aaca3257021e4c7abcefa74029c838db
work_keys_str_mv	AT linglingkong currentprogressandoutcomesofclinicaltrialsonusingepidermalgrowthfactorreceptortyrosinekinaseinhibitortherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT linlinwang currentprogressandoutcomesofclinicaltrialsonusingepidermalgrowthfactorreceptortyrosinekinaseinhibitortherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT ligangxing currentprogressandoutcomesofclinicaltrialsonusingepidermalgrowthfactorreceptortyrosinekinaseinhibitortherapyinnonsmallcelllungcancerpatientswithbrainmetastases AT jinmingyu currentprogressandoutcomesofclinicaltrialsonusingepidermalgrowthfactorreceptortyrosinekinaseinhibitortherapyinnonsmallcelllungcancerpatientswithbrainmetastases
_version_	1718393586444140544

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases

Ejemplares similares